Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NYSEAMERICAN:AZTR NASDAQ:ERNA OTCMKTS:INBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.53+1.3%$1.53$1.37▼$5.00$8.91M1.344,762 shs61,327 shsAZTRAzitra$0.53-8.1%$0.82$0.52▼$4.33$1.88M-1.691.77 million shs902,473 shsERNAErnexa Therapeutics$1.15-5.0%$1.32$1.09▼$18.75$8.82M5.62264,721 shs52,087 shsINBPIntegrated BioPharma$0.30+0.2%$0.29$0.22▼$0.42$9.19M0.9418,303 shs500 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-8.48%0.00%+4.86%-21.76%-64.88%AZTRAzitra-15.77%-23.06%-23.26%-63.24%-85.70%ERNAErnexa Therapeutics-3.15%-6.20%-9.02%-45.25%-91.85%INBPIntegrated BioPharma-4.52%-4.52%+4.94%+3.75%+14.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.53+1.3%$1.53$1.37▼$5.00$8.91M1.344,762 shs61,327 shsAZTRAzitra$0.53-8.1%$0.82$0.52▼$4.33$1.88M-1.691.77 million shs902,473 shsERNAErnexa Therapeutics$1.15-5.0%$1.32$1.09▼$18.75$8.82M5.62264,721 shs52,087 shsINBPIntegrated BioPharma$0.30+0.2%$0.29$0.22▼$0.42$9.19M0.9418,303 shs500 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-8.48%0.00%+4.86%-21.76%-64.88%AZTRAzitra-15.77%-23.06%-23.26%-63.24%-85.70%ERNAErnexa Therapeutics-3.15%-6.20%-9.02%-45.25%-91.85%INBPIntegrated BioPharma-4.52%-4.52%+4.94%+3.75%+14.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.33Hold$15.50913.07% UpsideAZTRAzitra 3.00Buy$4.00649.34% UpsideERNAErnexa Therapeutics 1.00SellN/AN/AINBPIntegrated BioPharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AZTR, APRE, INBP, and ERNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025APREAprea TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ERNAErnexa TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025APREAprea TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ERNAErnexa TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/24/2025AZTRAzitraMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.32 ➝ $4.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea TherapeuticsN/AN/AN/AN/A$3.55 per shareN/AAZTRAzitra$10K188.43N/AN/A$4.97 per share0.11ERNAErnexa Therapeutics$580K15.21N/AN/A$0.50 per share2.30INBPIntegrated BioPharma$54.35M0.17$0.06 per share4.62$0.66 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.32N/AN/AN/A-1,645.01%-78.90%-62.67%11/6/2025 (Estimated)AZTRAzitra-$8.97MN/A0.00N/AN/AN/A-183.57%-138.65%11/11/2025 (Estimated)ERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/AN/AN/A-682.08%11/11/2025 (Estimated)INBPIntegrated BioPharma$810K$0.0214.84∞N/A1.49%4.04%3.16%11/11/2025 (Estimated)Latest AZTR, APRE, INBP, and ERNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025N/AAZTRAzitra-$0.79N/AN/AN/AN/AN/A11/6/2025Q3 2025APREAprea Therapeutics-$0.11N/AN/AN/AN/AN/A9/23/2025Q4 2025INBPIntegrated BioPharmaN/A-$0.01N/A-$0.01N/A$14.18 million8/13/2025Q2 2025ERNAErnexa TherapeuticsN/A-$0.61N/A-$0.61N/AN/A8/12/2025Q2 2025APREAprea Therapeutics-$0.77-$0.53+$0.24-$0.53N/A$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AAZTRAzitraN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/AINBPIntegrated BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.345.34AZTRAzitraN/A1.241.24ERNAErnexa TherapeuticsN/A1.811.81INBPIntegrated BioPharma0.014.422.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%AZTRAzitra11.16%ERNAErnexa Therapeutics70.55%INBPIntegrated BioPharma25.25%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%AZTRAzitra0.25%ERNAErnexa Therapeutics4.49%INBPIntegrated BioPharma67.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.83 million5.03 millionNo DataAZTRAzitra103.53 million3.52 millionNot OptionableERNAErnexa Therapeutics107.67 million7.33 millionNo DataINBPIntegrated BioPharma15030.98 million10.16 millionNot OptionableAZTR, APRE, INBP, and ERNA HeadlinesRecent News About These CompaniesIntegrated BioPharma (OTCMKTS:INBP) Stock Price Down 4.5% - Here's WhyOctober 22 at 2:59 AM | americanbankingnews.comIntegrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025September 23, 2025 | accessnewswire.comAINBP Integrated BioPharma, Inc.June 15, 2025 | seekingalpha.comIntegrated BioPharma Reports Results for its Quarter Ended March 31, 2025May 14, 2025 | accessnewswire.comAIntegrated BioPharma Secures New Credit Line with PNCApril 21, 2025 | tipranks.comIntegrated BioPharma Reports Results for its Quarter Ended December 31, 2024February 13, 2025 | accessnewswire.comAIntegrated BioPharma Reports Results for its Quarter Ended September 30, 2024November 13, 2024 | accesswire.comAIntegrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024September 20, 2024 | accesswire.comAAbbott partners with maker of ‘bionic pancreas’September 5, 2024 | medtechdive.comMIntegrated Biopharma Inc (INBP)August 31, 2024 | investing.comShanghai unveils US$13.7 billion capital injection into IC, AI, and biopharma industriesAugust 1, 2024 | digitimes.comDIntegrated BioPharma, Inc. (INBP)July 19, 2024 | finance.yahoo.comIntegrated BioPharma Reports Results for its Quarter Ended March 31, 2024May 10, 2024 | accesswire.comAIntegrated nanoelectronics for the futureFebruary 19, 2024 | nature.comNIntegrated BioPharma Reports Results for its Quarter Ended December 31, 2023February 12, 2024 | finance.yahoo.comHow to buy the best integrated washing machineFebruary 2, 2024 | which.co.ukWKBI Biopharma and Argonaut form drug manufacturing allianceJanuary 17, 2024 | msn.comKBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug ...January 16, 2024 | businesswire.comJohnson & Johnson buys San Diego's Ambrx Biopharma for $2BJanuary 9, 2024 | msn.comWhat Is a Vertically Integrated Business Model?January 4, 2024 | smallbusiness.chron.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAZTR, APRE, INBP, and ERNA Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.53 +0.02 (+1.32%) Closing price 04:00 PM EasternExtended Trading$1.54 +0.01 (+0.98%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Azitra NYSEAMERICAN:AZTR$0.53 -0.05 (-8.11%) Closing price 04:10 PM EasternExtended Trading$0.52 -0.01 (-2.77%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.Ernexa Therapeutics NASDAQ:ERNA$1.15 -0.06 (-4.96%) Closing price 03:59 PM EasternExtended Trading$1.15 0.00 (0.00%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Integrated BioPharma OTCMKTS:INBP$0.30 +0.00 (+0.24%) As of 03:47 PM EasternIntegrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
